Giffoni de Mello Morais Mata, D.; Pezo, R.C.; Chan, K.K.W.; Menjak, I.; Eisen, A.; Trudeau, M.
A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. Curr. Oncol. 2025, 32, 6.
https://doi.org/10.3390/curroncol32010006
AMA Style
Giffoni de Mello Morais Mata D, Pezo RC, Chan KKW, Menjak I, Eisen A, Trudeau M.
A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. Current Oncology. 2025; 32(1):6.
https://doi.org/10.3390/curroncol32010006
Chicago/Turabian Style
Giffoni de Mello Morais Mata, Danilo, Rossanna C. Pezo, Kelvin K. W. Chan, Ines Menjak, Andrea Eisen, and Maureen Trudeau.
2025. "A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer" Current Oncology 32, no. 1: 6.
https://doi.org/10.3390/curroncol32010006
APA Style
Giffoni de Mello Morais Mata, D., Pezo, R. C., Chan, K. K. W., Menjak, I., Eisen, A., & Trudeau, M.
(2025). A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer. Current Oncology, 32(1), 6.
https://doi.org/10.3390/curroncol32010006
